Logos Global Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Logos Global Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-700,000	Closed	-$15.3M	–	74
2023 Q3	$15.3M	Buy	+700,000	New	+$17.5M	2.04%	18
2023 Q1	–	Sell	-260,000	Closed	-$8.2M	–	50
2022 Q4	$8.2M	Buy	+260,000	New	+$7.34M	0.96%	28
2021 Q1	–	Sell	-100,000	Closed	-$1.66M	–	75
2020 Q4	$1.66M	Buy	+100,000	New	+$1.3M	0.14%	55

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Logos Global Management's CERE Position: Q4 2023 in Review

Logos Global Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 700,000 shares — an estimated $15.3M sold.

Logos Global Management first reported a position in CERE in Q4 2020 and held it in 3 quarters. The position peaked at $15.3M in Q3 2023. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

Logos Global Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Logos Global Management sold 700,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $15.3M.
Logos Global Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
Logos Global Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $15.3M in Q3 2023.
195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.